Acute Myeloid Leukemia (AML) Awareness Day: Evolving Treatment Directions With Dr. Tristan Knight, Dr. Richa Thakur, and Dr. Joseph Kalis

In honor of Acute Myeloid Leukemia (AML) Awareness Day, Oncology Data Advisor Editorial Board and Fellows Forum members Tristan Knight, MD, FRCPC, Richa Thakur, MD, and Joseph Kalis, PharmD, BCOP, hosted a live panel discussion covering the evolving treatment landscape for AML, including:

  • Novel therapies and combinations such as chimeric antigen receptor (CAR) T-cell therapy and isocitrate dehydrogenase (IDH) inhibitors
  • The role of measurable residual disease (MRD) testing
  • Considerations for pediatric transplant and cellular therapy
  • Words of hope for patients undergoing treatment for AML

Additionally, they answered live questions from the audience, including:

  • Do you have any first-line treatment recommendations for patients with a KMT2A mutation?
  • When do recommend that patients participate in a clinical trial?

Watch the video to hear the panelists’ answers to these questions and their perspectives on the ever-changing therapeutic landscape for AML! 

About the Panelists

Tristan E. Knight, MD, FRCPC, is a Clinical Assistant Professor of Pediatrics at the University of Washington (Seattle, WA) and practices at Seattle Children’s Hospital. He completed his Pediatric Residency at the University of Hawaii, a Pediatric Hematology/Oncology Fellowship at the Children’s Hospital of Michigan, and a Bone Marrow Transplant (BMT)/Cellular Therapy Fellowship at the Hospital for Sick Children (SickKids). His clinical areas of interest are allogeneic/autologous BMT and cellular/immune effector cell therapy, particularly in the treatment of children with ALL, AML, and neuroblastoma. He has published extensively on novel therapeutic approaches in these conditions, including the use of CAR T-cell therapy in children.

Richa Thakur, MD, is both a Palliative Care Physician and Hematology/Oncology Fellow at Zucker School of Medicine at Hofstra/Northwell Health. She graduated from Washington University in St. Louis with a bachelor’s in chemistry, medical school at Texas A&M, residency in Internal Medicine, and a fellowship Palliative Care at Zucker School of Medicine. Her research interests include improving quality of life in patients diagnosed with hematologic malignancies.

Joseph Kalis, PharmD, BCOP, is an Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health. In this position, he educates patients about their chemotherapy and immunotherapy treatments, reviews treatment plans and dose adjustments, and assists with supportive care. Dr. Kalis’ professional interests include multiple myeloma and hematologic malignancies. He enjoys teaching learners from all walks of life. Dr. Kalis has spoken extensively for continuing education programs, along with various peer-reviewed papers on oncology and pharmacy. 

Related Articles

Responses

Your email address will not be published. Required fields are marked *